凝血酶激活的纤溶抑制物与冠心病关系研究

doi:10.19485/j.cnki.issn2096-5087.2020.12.005

Preventive Medicine

2020, Vol. 32

Issue (12): 1208-1212 DOI: 10.19485/j.cnki.issn2096-5087.2020.12.005

Current Issue | Archive | Adv Search

The relationship between thrombin activatable fibrinolysis inhibitor and coronary heart disease

ZHAO Mengnan^*, TIAN Peiru, QIU Li, LI Yuning, WANG Xiaonan, YI Boyu, SHI Jingpu

^*Department of Clinical Epidemiology and Evidence-based Medicine, The First Hospital of China Medical University, Shenyang, Liaoning 110001, China

Abstract
Figure/Table
References
Related Citation (10)

Download: PDF (1034 KB) HTML (0 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the relationship between thrombin activatable fibrinolysis inhibitor ( TAFI ) and coronary heart disease ( CHD ), and to provide evidence for the prevention of CHD. Methods The patients with CHD in Fushun Central Hospital in Liaoning Province were selected as the case group, the patients without CHD in the same hospital and period were selected as the control group. The demographic information and clinical examination results ( serum TAFI, lipid, glucose, etc. ) were collected to analyze the association between TAFI and CHD by logistic regression models.The multivariate logistic regression analysis was used to explore the relationship between TAFI and CHD. Results There were 222 cases, including 100 cases of stable angina, 44 cases of unstable angina and 78 cases of acute myocardial infarction, and 222 controls. The median ages of cases and controls were 62 and 57 years old. The results of multivariate logistic regression analysis showed that serum TAFI>22.88 μg/mL ( P₇₅ of controls ) was associated with the risk of CHD ( OR=1.619, 95%CI: 1.011-2.593 ), unstable angina ( OR=2.917, 95%CI: 1.433-5.939 ) and acute myocardial infarction ( OR=2.626, 95%CI: 1.007-6.847 ). Conclusion The high level of TAFI is related to CHD, unstable angina and acute myocardial infarction.

Key words： thrombin activatable fibrinolysis inhibitor coronary heart disease case-control study

Received: 15 July 2020 Revised: 29 August 2020 Published: 10 December 2020

ZTFLH:

R541.4

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHAO Mengnan
	TIAN Peiru
	QIU Li
	LI Yuning
	WANG Xiaonan
	YI Boyu
	SHI Jingpu

Cite this article:

ZHAO Mengnan,TIAN Peiru,QIU Li, et al. The relationship between thrombin activatable fibrinolysis inhibitor and coronary heart disease[J]. Preventive Medicine, 2020, 32(12): 1208-1212.

URL:

http://www.zjyfyxzz.com/EN/10.19485/j.cnki.issn2096-5087.2020.12.005 OR http://www.zjyfyxzz.com/EN/Y2020/V32/I12/1208

[1] 胡盛寿,杨跃进,郑哲,等.《中国心血管病报告2018》概要[J].中国循环杂志,2019,34(3):209-220.
[2] YILDIRIM M N,SELCOKI Y,UYSAL S,et al.Thrombin activatable fibrinolysis inhibitor:its role in slow coronary flow[J].Herz,2014,39(8):993-1000.
[3] BRIDGE K I,BOLLEN L,ZHONG J,et al.Thrombin-activatable fibrinolysis inhibitor in human abdominal aortic aneurysm disease[J]. J Thromb Haemost,2017,15(11):2218-2225.
[4] PLUG T,MEIJERS J C.Structure-function relationships in thrombin-activatable fibrinolysis inhibitor[J]. J Thromb Haemost,2016,14(4):633-644.
[5] 江明华,吴连拼,陶红群,等. 汉族人凝血酶活化的纤溶抑制物编码区的基因多态性与冠状动脉粥样硬化性心脏病相关性研究[J].中华检验医学杂志,2007,30(9):1017-1022.
[6] 中华医学会心血管病学分会.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206.
[7] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志,2015,43(5):380-393.
[8] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.非ST段抬高型急性冠状动脉综合征诊断和治疗指南(2016)[J].中华心血管病杂志,2017,45(5):359-376.
[9] DAI H X,SHI J P,HE Q,et al.Dose-response relationship between thrombin-activatable fibrinolysis inhibitor (TAFI) and stroke:a Chinese case-control study[J]. Med Sci Monit,2017,23:4376-4381.
[10] SCHROEDER V,CHATTERJEE T,MEHTA H,et al.Thrombin activatable fibrinolysis inhibitor(TAFI)levels in patients with coronary artery disease investigated by angiography[J].Thromb Haemost,2008,88(7):1020-1025.
[11] BOFFA M B,NESHEIM M E,KOSCHINSKY M L.Thrombin activable fibrinolysis inhibitor(TAFI):molecular genetics of an emerging potential risk factor for thrombotic disorders[J].Curr Drug Targets Cardiovasc Haematol Disord,2001,1(2):59-74.
[12] LEUNG L L,MYLES T,NISHIMURA T,et al.Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B(or TAFI)[J].Mol Immunol,2008,45(16):4080-4083.
[13] 吴连拼,江明华,黄明远,等.急性冠脉综合征患者pentraxin-3与凝血酶活化的纤溶抑制物的变化[J].心脑血管病防治,2012,12(6):447-448.
[14] DE BRUIJNE E L E,GILS A,GUIMARÃES A H C,et al.The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age:the ATTAC study[J]. J Thromb Haemost,2009,7(6):919-927.
[15] 梁红英,邝开安,张淑玲.心肌梗死患者凝血酶激活纤溶抑制物与纤维蛋白原的关系研究[J].实用心脑肺血管病杂志,2011,19(1):83.
[16] 张铭朋,刘向群,许玲,等.老年不稳定性心绞痛患者血浆凝血酶激活纤溶抑制物的变化及低分子量肝素的治疗作用[J].中国老年学杂志,2007,27(17):1688-1690.
[17] 李桂艳,李萍,贾明利,等.凝血酶激活纤溶抑制物散射比浊法检测结果临床应用评估[J].临床军医杂志,2016,44(10):1059-1061.
[18] PAOLA C A,ANTONUCCI E,LIOTTA A A,et al.TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit[J]. Thromb Res,2006,118(4):495-500.